ITALIEN

EQS-News: Energy S.p.a.: GBC Research initiates coverage with buy recommendation and target price of EUR 2.75 

Retrieved on: 
Friday, May 3, 2024
Smart, ENY, XL, Research, BESS, Wind, CAAB, GBC, Growth

Strong market position in the field of Battery Energy Storage Systems (BESS) on the Italian domestic market.

Key Points: 
  • Strong market position in the field of Battery Energy Storage Systems (BESS) on the Italian domestic market.
  • Sant'Angelo di Piove di Sacco (Padua, Italien), April 18, 2024 – GBC Research has added Energy S.p.a. (ISIN IT0005500712, ticker ENY) to its coverage.
  • Based on the detailed initial study, the analysts recommend buying the shares of the specialist for Battery Energy Storage Systems.
  • In 2026, Energy is expected to generate sales of EUR 83.46 million and EBITDA of EUR 14.70 million.

Correction of a release from 12.03.2024 18:00 CET/CEST - TaTaTu S.p.A.: FINANCIAL CALENDAR 2024

Retrieved on: 
Friday, May 3, 2024
TaTaTu, Correction, Bank statement, Public offering, Audit

Correction of a release from 12.03.2024 18:00 CET/CEST - TaTaTu S.p.A.: FINANCIAL CALENDAR 2024

Key Points: 
  • Correction of a release from 12.03.2024 18:00 CET/CEST - TaTaTu S.p.A.: FINANCIAL CALENDAR 2024
    Dissemination of a French Regulatory News, transmitted by EQS Group.
  • The issuer is solely responsible for the content of this announcement.
  • NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, OR JAPAN
    Rome, April 15th 2024 - Tatatu S.p.A. (the “Company”) that owns TaTaTu, an entertainment platform based on data sharing economy and circular economy, listed through Direct Listing of shares on Euronext Growth Paris (ticker code: ALTTU), hereby announces that the Board of Directors meeting today acknowledged the need for further examination into the financial structure of the Company and the Group and therefore decided the new dates for the approval of the financial statements and consolidated financial statements for 2023:
    - 27 May 2024: Meeting of the Board of Directors to examine and approve the proposed 2023 statutory financial statements and the 2023 consolidated financial statements;
    - 27 June 2024: Shareholders' meeting to approve the statutory financial statements and review the consolidated financial statements for the 2023 financial year;
    Furthermore, starting from 4/16/2024, Fernando Palladino will replace Matteo Colafigli as investor relator of Tatatu S.p.A.

EQS-News: NOTICE OF CALL OF THE ORDINARY SHAREHOLDERS' MEETING

Retrieved on: 
Friday, May 3, 2024
Annual general meeting, Prejudice, News, Communication, Proxy, Approval, Exercise, Documentation, Shareholder, Record, Legislation, Bank statement, Credit, Legislature, Person, Security (finance)

The share capital is equal to Euro 368,981.06 divided into 2,592,984 ordinary shares without indication of par value; each share entitles the holder to one vote in the Company's ordinary and extraordinary shareholders' meetings.

Key Points: 
  • The share capital is equal to Euro 368,981.06 divided into 2,592,984 ordinary shares without indication of par value; each share entitles the holder to one vote in the Company's ordinary and extraordinary shareholders' meetings.
  • To this end, the appropriate proxy form is available on the Company's website at the address https://rigsave.com/ , in the "Investor Relations" section, "Shareholders' Meeting".
  • Shareholders are entitled to attend the shareholders' meeting and exercise their right to vote also by audio-video-conference.
  • Shareholders are invited to connect via audio-video-conference as early as necessary to ensure the holding of the Shareholders' Meeting.

EQS-News: Newron presents 2023 financial results and provides 2024 outlook

Retrieved on: 
Wednesday, April 10, 2024
Psychosis, Schizophrenia, Clozapine, XETRA, Patient, CNS, Business development, Peripheral nervous system, Psychedelic literature, Safety, TRS, PANSS, EIB, Canadian International Council, Pharmaceutical industry

Milan, Italy, March 19, 2024, 07:00 am CET – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced its financial results and operational highlights for the business year ended December 31, 2023, and provided an outlook for 2024.

Key Points: 
  • Milan, Italy, March 19, 2024, 07:00 am CET – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced its financial results and operational highlights for the business year ended December 31, 2023, and provided an outlook for 2024.
  • Results from the first 100 patients to complete six months (30 weeks) of treatment with evenamide were reported in January, followed by results in February 2023 from the same 100-person cohort at the one-year (52 weeks) timepoint.
  • These data were further strengthened, post-period in January 2024, with the final results from study 015 reviewing all study participants after one year of treatment.
  • Patient enrollment has completed and results from this study are expected in April 2024.

EQS-News:  Newron enters into an agreement for the subscription of up to 2.05 million newly issued shares; Proceeds of up to EUR 15.0 million 

Retrieved on: 
Wednesday, April 10, 2024
EUR, Frankfurt Stock Exchange, XETRA, CFO, Patient, CNS, SIX Swiss Exchange, Peripheral nervous system, Security (finance)

Newron enters into an agreement for the subscription of up to 2.05 million newly issued shares; Proceeds of up to EUR 15.0 million

Key Points: 
  • Newron enters into an agreement for the subscription of up to 2.05 million newly issued shares; Proceeds of up to EUR 15.0 million
    The issuer is solely responsible for the content of this announcement.
  • Under the agreement, the fund subscribes to an initial 750,000 newly issued shares at a subscription price of EUR 7.33 per share, which corresponds to gross proceeds of approximately EUR 5.5 million.
  • In addition, the fund has a right to subscribe to an additional up to 1,300,000 newly issued shares until no later than January 31, 2025, at a subscription price to be calculated pursuant to an agreed formula.
  • “The investment by this specialist institutional fund is a validation of our strategy to develop innovative CNS therapies,” said Roberto Galli, CFO of Newron.

EQS-News: Newron announces agreement with the European Investment Bank (EIB) to extend the near-term tranche repayment dates of its 2018 financing agreement

Retrieved on: 
Wednesday, April 10, 2024
EIB, Peripheral nervous system, Patient, CNS, Schizophrenia, XETRA, European Investment Bank, BofA Securities, Pharmaceutical industry

Under the amendment, repayment of tranches one to three (out of a total of five) of the financing agreement with due dates from June 2024 to April 2025 will be shifted substantially, with tranche one now scheduled for November 25, 2025, tranche two for April 2026 and tranche three for June 2026.

Key Points: 
  • Under the amendment, repayment of tranches one to three (out of a total of five) of the financing agreement with due dates from June 2024 to April 2025 will be shifted substantially, with tranche one now scheduled for November 25, 2025, tranche two for April 2026 and tranche three for June 2026.
  • The due dates for tranches four and five will stay unchanged.
  • On the amended tranches, Newron will start paying the agreed interest rates.
  • Details of the 2018 loan agreement can be found in Newron’s 2022 Annual Report which is posted on its website.

EQS-News: Data from Newron’s study 014/015 and an evenamide clinical development outlook presented at the 2024 Annual Congress of the Schizophrenia International Research Society (SIRS)

Retrieved on: 
Wednesday, April 10, 2024
SIRS, Schizophrenia, Clozapine, XETRA, Incidence, Patient, CNS, Peripheral nervous system, Safety, TRS, Schizophrenia International Research Society, Pharmaceutical industry

The data presented were detailing previously reported scientific results of study 014/015, the future clinical development outlook for evenamide and information on study 008A.

Key Points: 
  • The data presented were detailing previously reported scientific results of study 014/015, the future clinical development outlook for evenamide and information on study 008A.
  • As previously announced by Newron, the study showed that the addition of evenamide to antipsychotics was well tolerated, with low incidence of treatment-emergent adverse events.
  • Treatment with evenamide was associated with sustained, clinically significant benefit that increased throughout the one-year course of treatment.
  • Study 008A is a four-week, randomized, double-blind and placebo-controlled study assessing the efficacy, tolerability, and safety of evenamide (30 mg bid).

Correction of a release from 20.12.2023 19:00 CET/CEST - TaTaTu S.p.A.: FINANCIAL CALENDAR 2024

Retrieved on: 
Wednesday, March 13, 2024
TaTaTu, Public offering, Calendar, Correction

Correction of a release from 20.12.2023 19:00 CET/CEST - TaTaTu S.p.A.: FINANCIAL CALENDAR 2024

Key Points: 
  • Correction of a release from 20.12.2023 19:00 CET/CEST - TaTaTu S.p.A.: FINANCIAL CALENDAR 2024
    Dissemination of a French Regulatory News, transmitted by EQS Group.
  • The issuer is solely responsible for the content of this announcement.
  • 27 September 2024: Board of Directors, approval of the half-yearly financial statements as at 30 June 2024 as subject to voluntary auditing.
  • This press release and the corporate events calendar are available on the Company's website at the following address https://corporate.tatatu.com/en/corporate/ Investors section/Financial Calendar.

TaTaTu S.p.A.: ALEPH FINANCE APPOINTED NEW LISTING SPONSOR

Retrieved on: 
Wednesday, March 13, 2024
TaTaTu, Public offering, Security (finance)

Dissemination of a French Regulatory News, transmitted by EQS Group.

Key Points: 
  • Dissemination of a French Regulatory News, transmitted by EQS Group.
  • The issuer is solely responsible for the content of this announcement.
  • NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, OR JAPAN
    Rome, March 7th 2024 - Tatatu S.p.A. (the “Company”) that owns TaTaTu, an entertainment platform based on data sharing economy and circular economy, listed through Direct Listing of shares on Euronext Growth Paris (ticker code: ALTTU), hereby notifies that starting from March 19th 2024, Aleph Finance (trading name of U Capita Asset Management LLP) has been appointed as the new listing sponsor of Tatatu S.p.A replacing Portzamparc BNP Paribas Group.

EQS-News:  Energy S.p.A. is attending two renewable sector trade exhibitions: KEY Energy in Rimini and MCE Expocomfort in Milan

Retrieved on: 
Wednesday, March 13, 2024
XL, MCE, Agrivoltaics, C&I, CAAB, Borsa Italiana, Rho, Acceleration, Energy, Smart, Renewable energy

Energy S.p.A. is attending two renewable sector trade exhibitions: KEY Energy in Rimini and MCE Expocomfort in Milan

Key Points: 
  • Energy S.p.A. is attending two renewable sector trade exhibitions: KEY Energy in Rimini and MCE Expocomfort in Milan
    The issuer is solely responsible for the content of this announcement.
  • Energy S.p.A. is attending two renewable sector trade exhibitions:
    The two events will be held respectively from February 28 to March 1 at the Rimini Fair and from March 12 to 15 at Milano Fiera in Rho.
  • These events are pivotal in Italy and abroad for the entire renewable energy sector and provide significant training and information opportunities regarding energy and the acceleration of the energy transition process.
  • “ MCE – Mostra Convegno Expocomfort ” to be held from March 12 to 15 at Milano Fiera in Rho (Milan).